Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872534 · ClinicalTrials.gov registry record · Phase 1
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
A Phase 1 study, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 204
- Enrollment target
NCT00872534: Completed Phase 1 study, sponsored by PLx Pharma.
NCT00872534 is a Phase 1 study that has completed, run by PLx Pharma. The registered enrollment target is 204 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (240% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00872534, a Phase 1 study, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 204 participants
- Enrollment target
Study Summary
To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.
Primary Outcome
Incidence of subjects with gastroduodenal composite scores of 3 or 4 (\> 5 erosions or 1 or more ulcers 3 mm or greater in length with unequivocal depth).
Interventions
- DRUG acetylsalicylic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
What the finished NCT00872534 record still lists
NCT00872534 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (240% higher).
The record links to 0 conditions, and to 1 intervention - of which acetylsalicylic acid is the first listed.
NCT00872534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00872534 about?
NCT00872534 is a clinical study titled "Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers". To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.
What is the current status of trial NCT00872534?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 204 participants. The study started on 2009-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00872534?
The interventions under investigation include: acetylsalicylic acid (DRUG).
Who is sponsoring clinical trial NCT00872534?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00872534's enrollment target sits among peer trials
204 256th of 2000 higher than 1,743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia